Advances on the Therapeutic Potential of Cell Receptor Activation in Glioblastoma

Overview

Journal Mol Biol Rep

Date 2025 Feb 5

PMID 39907852

Authors

Gerson G Contreras-Chavez

Luis A Zapi-Colin

Irazu Contreras

Jose A Estrada

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme is the most common and aggressive malignant brain tumor. Current therapies have been unable to improve life expectancy in patients. This cancer is frequently accompanied by overexpression of receptors, such as EGFR, VEGFR and TLRs, involved in the regulation of inflammation, cell proliferation, differentiation, and survival. The present review summarizes current knowledge from preclinical and clinical studies investigating the role of pattern recognition and tyrosine kinase receptors in glioblastoma development and evolution, and their possible use to improve treatment outcomes and patient survival.

References

Brown T, Brennan M, Li M, Church E, Brandmeir N, Rakszawski K . Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2016; 2(11):1460-1469. PMC: 6438173. DOI: 10.1001/jamaoncol.2016.1373. View

Hanif F, Muzaffar K, Perveen K, Malhi S, Simjee S . Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev. 2017; 18(1):3-9. PMC: 5563115. DOI: 10.22034/APJCP.2017.18.1.3. View

Repici A, Ardizzone A, Luca F, Colarossi L, Prestifilippo A, Pizzino G . Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma. Cells. 2024; 13(4. PMC: 10886920. DOI: 10.3390/cells13040361. View

Tilak M, Holborn J, New L, Lalonde J, Jones N . Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. Int J Mol Sci. 2021; 22(4). PMC: 7918566. DOI: 10.3390/ijms22041831. View

Sharma P, Debinski W . Receptor-Targeted Glial Brain Tumor Therapies. Int J Mol Sci. 2018; 19(11). PMC: 6274942. DOI: 10.3390/ijms19113326. View

Glas M, Coch C, Trageser D, Dassler J, Simon M, Koch P . Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells. 2013; 31(6):1064-74. DOI: 10.1002/stem.1350. View

Brandenburg S, Blank A, Bungert A, Vajkoczy P . Distinction of Microglia and Macrophages in Glioblastoma: Close Relatives, Different Tasks?. Int J Mol Sci. 2020; 22(1). PMC: 7794706. DOI: 10.3390/ijms22010194. View

Zhang B, Shen R, Cheng S, Feng L . Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme. Cancer Med. 2019; 8(6):2897-2907. PMC: 6558448. DOI: 10.1002/cam4.2192. View

Du Z, Lovly C . Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018; 17(1):58. PMC: 5817791. DOI: 10.1186/s12943-018-0782-4. View

10.

Chen S, Li X, Wang H, Chen G, Zhou Y . Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma. Biochem Biophys Res Commun. 2022; 604:158-164. DOI: 10.1016/j.bbrc.2022.03.045. View

11.

Herrlinger U, Schafer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R . Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. 2016; 34(14):1611-9. DOI: 10.1200/JCO.2015.63.4691. View

12.

Geindreau M, Ghiringhelli F, Bruchard M . Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response. Int J Mol Sci. 2021; 22(9). PMC: 8124522. DOI: 10.3390/ijms22094871. View

13.

Goel H, Mercurio A . VEGF targets the tumour cell. Nat Rev Cancer. 2013; 13(12):871-82. PMC: 4011842. DOI: 10.1038/nrc3627. View

14.

Mabeta P, Steenkamp V . The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy. Int J Mol Sci. 2022; 23(24). PMC: 9779738. DOI: 10.3390/ijms232415585. View

15.

Wefel J, Armstrong T, Pugh S, Gilbert M, Wendland M, Brachman D . Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro Oncol. 2021; 23(7):1125-1138. PMC: 8661434. DOI: 10.1093/neuonc/noab011. View

16.

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

17.

Pham K, Luo D, Siemann D, Law B, Reynolds B, Hothi P . VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. Cancer Lett. 2015; 360(1):60-7. PMC: 7294457. DOI: 10.1016/j.canlet.2015.02.005. View

18.

Lu J, Hu Y, Qian R, Zhang Y, Yang X, Luo P . Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib. Eur J Pharmacol. 2020; 874:173022. DOI: 10.1016/j.ejphar.2020.173022. View

19.

Piao Y, Park S, Henry V, Smith B, Tiao N, Flynn D . Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 2016; 18(9):1230-41. PMC: 4998992. DOI: 10.1093/neuonc/now030. View

20.

Kang Z, Li S, Lin Y, Li Y, Mao Y, Zhang J . A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors. Invest New Drugs. 2023; 41(2):296-305. PMC: 10140125. DOI: 10.1007/s10637-022-01325-4. View